We speculate that this can serve as a rescue mechanism for cancer cells during mTOR-targeted cancer therapy as Rapamycin treatment leads to decreased binding of NM1 and active histone marks around transcription start sites of mitochondrial transcription factors similar to NM1 KO cells. Here, MTOR is linked to cancer.